Spectral Medical Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EDTXF research report →
Companywww.spectraldx.com
Spectral Medical Inc. , together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.
- CEO
- Christopher Seto
- IPO
- 2009
- Employees
- 29
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $296.35M
- P/E
- -10.64
- P/S
- 146.66
- P/B
- -5.72
- EV/EBITDA
- -12.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -79.25%
- Op Margin
- -412.28%
- Net Margin
- -1377.18%
- ROE
- 61.00%
- ROIC
- 26.25%
Growth & Income
- Revenue
- $2.44M · 6.74%
- Net Income
- $-47,653,133 · -209.40%
- EPS
- $-0.16 · -190.91%
- Op Income
- $-11,675,477
- FCF YoY
- -9.88%
Performance & Tape
- 52W High
- $1.31
- 52W Low
- $0.58
- 50D MA
- $1.00
- 200D MA
- $0.99
- Beta
- 0.36
- Avg Volume
- 8.03K
Get TickerSpark's AI analysis on EDTXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our EDTXF Coverage
We haven't published any research on EDTXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EDTXF Report →